Elekta Presents Strategic Agenda To Outgrow The Market

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM, June 17 – During a capital markets day in Stockholm today, Elekta President and CEO, Niklas Savander, underpinned the company’s ambition to return to growth levels above 10 percent. “The growth drivers behind radiation therapy are striking. Elekta is very well positioned to capture the potential,” he said. He elaborated on the market opportunity for Elekta, particularly in emerging markets, which account for 35 percent of its business, and gave insight into a research-based market model that Elekta uses to calculate global growth levels.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC